

Standard Operating Procedure (SOP) *Candida albicans* Murine Invasive Candidiasis Model NIH/NIAID Task Order A13

Isolates:

The murine model of invasive candidiasis described below has been validated with two separate wild-type isolates of *Candida albicans* that are susceptible to clinically available antifungal agents. These include:

- American Type Culture Collection (ATCC) isolate 90028, which is used as a reference strain for antifungal susceptibility testing by the Clinical and Laboratory Standards Institute (CLSI; reference guidelines M27-A3) [1]
- SC5314 for which the genome has been sequenced and is available (www.candidagenome.org/) [2]

Mice:

Two strains of mice have been extensively evaluated and used in this model of invasive candidiasis. These include:

- Outbred ICR (CD-1) strain [3-6]
- Inbred BALB/c strain [7, 8]

Suppliers for both strains that have been used include Harlan (www.harlan.com) and Charles River (www.criver.com). The typical weight and age range used for each mouse strain is shown in the table below:

Strain	Weight	Age
ICR (CD-1)	22 - 30 grams	4 - 5 weeks
BALB/c	20 - 24 grams	7 - 12 weeks

Immunosuppression:

This murine model may be performed using immunocompetent or immunocompromised mice. A single dose of 5-fluorouracil may be used to render the mice neutropenic.

- 5-fluorouracil (50 mg/mL vial) is used without further dilutions.
- Administer a 0.1 mL dose per mouse intravenously one day prior to inoculation.
- This single dose results in profound and prolonged neutropenia (< 100 neutrophils/mm³ for >10 days) [9].

Inoculum Preparation and Quantification:

- Subculture the *C. albicans* strain twice at 37°C for 48 hours on Sabouraud dextrose agar prior to in vivo use.
- Place isolates taken from the second subculture into 50 mL of brain heart infusion broth and allow to grow overnight (~18-24 hours) in a shaking incubator at 37°C and 150 rpm.
 - Alternatively, the isolates can be initially subcultured on YPD agar plates. Subsequent subcultures can be grown in YPD broth at 25 - 30°C.
- Collect the cells by centrifugation (~2,000 rpm for 10 minutes) and wash in sterile physiologic saline or sterile phosphate buffered saline (PBS). Remove the

supernatant and repeat the wash 2 additional times in sterile physiologic saline or sterile PBS. After the second wash collect a loopful (10 ul) of cells and place into 2 mL of sterile saline or PBS. Spin in a microcentrifuge at high speed for 3 minutes. Discard the supernatant and then resuspend the cells in 2 mL of sterile saline or PBS.

- Alternatively, the cells may be washed once in sterile saline or PBS
- Prepare dilutions of the cells in sterile saline or PBS (e.g., 1:200 to 1:400 or 1:1000 to 1: 10,000) and determine the number of cells/mL using a hemocytometer.
 - Adjust the desired infecting inoculum (e.g., 6.25×10^5 to 7.5×10^6 cells/mL depending on the weight of the mice and the *C. albicans* strain that is used).
 - Alternatively, the inoculum may be adjusted by optical density of **0.800** ($\sim 1.7 \times 10^7$ /ml) using a spectrophotometer at a wavelength of 490 nm then dilute 1:10 followed by a second dilution to the target concentration. Following preparation using a spectrophotometer check the inoculum using a haemocytometer readjust if necessary
 - The inoculum should be used to infect the mice within 2 hours of preparation. It is essential to regularly resuspend the suspension during the infection.
- Confirm the inoculum viability by serially diluting an aliquot of the inoculum in sterile saline or phosphate buffered saline. Prepare serial dilutions (e.g., 1:1000, 1:10,000, and 1:100,000) of the stock, and plate 100 microliters of the dilutions onto Sabouraud dextrose agar (may be done in duplicate for each dilution). Incubate the plates at 37°C and count the number of colonies the next day.
- On the day of inoculation weigh each mouse and determine the average weight. The average weight will be used to calculate the inoculum that will be delivered. The inoculum that is delivered is corrected for both the *C. albicans* strain that is used and the average weight of the mice as follows:

Average Weight 20 grams

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 20 g)	Cells/mL (0.2 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.0×10^6 cells/mouse	5.0×10^6 cells/mL
SC5314	5,000 cells/gram	1.0×10^5 cells/mouse	5.0×10^5 cells/mL

Average Weight 25 grams

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 25 g)	Cells/mL (0.2 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.25×10^6 cells/mouse	6.25×10^6 cells/mL
SC5314	5,000 cells/gram	1.25×10^5 cells/mouse	6.25×10^5 cells/mL

Average Weight 30 grams

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 30 g)	Cells/mL (0.2 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.5 x 10 ⁶ cells/mouse	7.5 x 10 ⁶ cells/mL
SC5314	5,000 cells/gram	1.5 x 10 ⁵ cells/mouse	7.5 x 10 ⁵ cells/mL

Alternatively, the volume used for the infecting inoculum can be adjusted based on the mouse weight thus keeping the cell concentration constant:

Average Weight 20 grams (inoculation volume 0.20 mL)

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 20 g)	Cells/mL (0.2 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.0 x 10 ⁶ cells/mouse	5.0 x 10 ⁶ cells/mL
SC5314	5,000 cells/gram	1.0 x 10 ⁵ cells/mouse	5.0 x 10 ⁵ cells/mL

Average Weight 25 grams (inoculation volume = 0.25 mL)

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 25 g)	Cells/mL (0.25 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.25 x 10 ⁶ cells/mouse	5.0 x 10 ⁶ cells/mL
SC5314	5,000 cells/gram	1.25 x 10 ⁵ cells/mouse	5.0 x 10 ⁵ cells/mL

Average Weight 30 grams (inoculation volume = 0.30 mL)

<i>C. albicans</i> strain	Cells/gram	Cells/mouse (Ave. wt. 30 g)	Cells/mL (0.3 mL inocul.vol.)
ATCC 90028	50,000 cells/gram	1.5 x 10 ⁶ cells/mouse	5.0 x 10 ⁶ cells/mL
SC5314	5,000 cells/gram	1.5 x 10 ⁵ cells/mouse	5.0 x 10 ⁵ cells/mL

Intravenous Inoculation:

- Inoculate each mouse by injecting 0.2 mL of the desired inoculum in sterile saline or PBS via the lateral tail vein.
 - As shown above, an alternate strategy is to keep the cell concentration constant (5.0 x 10⁵ or 5.0 x 10⁶ cells/mL) and change the volume of the infecting inoculum based on the mouse weight (e.g., 0.2 mL for a 20 g mouse, 0.25 mL for a 25 g mouse, and 0.3 mL for a 30 gram mouse)
- If necessary, a heat lamp, a heated box, and/or alcohol wipe may be used to dilate the vein for better visualization.

- If necessary, briefly apply slight pressure over injection site to prevent bleeding
- Following successful inoculation, return the mice to their cages.

Monitoring of Animals Post-Inoculation:

- Following inoculation, mice should be monitored at least twice daily throughout the course of the experiment to prevent and minimize unnecessary pain and distress. Moribund animals will be identified by the following criteria:
 1. Ruffled and/or matted fur
 2. Weight loss (e.g., >20%)
 3. Hypothermia (cool to touch)
 4. Decreased activity
 5. Hunched posture
 6. Inability to eat or drink
 7. Torticollis or barrel rolling

Any animal displaying more than one of these criteria should be humanely euthanized using two forms of approved euthanasia (e.g., 5% isoflurane or pentobarbital anesthesia followed by exsanguination via cardiac puncture and cervical dislocation).

Antifungal Therapy:

- To evaluate the effects of therapy, initiate antifungal treatment after intravenous inoculation. In order to allow for the establishment of disease, begin therapy the day after inoculation (~24 hours later).
- Treatment groups typically consist of the following:
 1. Placebo controls (either saline or an excipient used to dissolve or suspend one of the positive comparators)
 2. Test compound
 3. Positive control (e.g., fluconazole, caspofungin, amphotericin B formulation)
- Examples of doses and dosing calculations for fluconazole and caspofungin are given at the end of this SOP.

Outcome Measures: Outcome measures of antifungal therapy that are commonly used include reductions in tissue fungal burden at a pre-specified time point and survival. Daily weights may be recorded and changes in weight can also be used as an outcome measure.

Fungal Burden. Fungal burden should be measured at a pre-specified time point following the initiation of antifungal therapy. To help control for antifungal carry-over, this time point should be at least one day after antifungal therapy is stopped (e.g., day 6 if therapy is on days 1 - 5, or day 8 if therapy is on days 1 - 7).

- At the pre-specified time point, aseptically collect the desired target organ(s) (e.g., kidneys, liver, spleen, and brains as needed), and record the weight of each organ for each animal.

- Place the organs into an appropriate volume of sterile saline or PBS (e.g., range of 1 - 5 mL) and homogenize using either a tissue grinder or tissue homogenizer.
- Prepare appropriate dilutions (e.g., 1:10, 1:100, 1:1000) in sterile water or PBS and plate an appropriate volume (e.g., 0.1 - 0.2 mL) of each onto Sabouraud dextrose agar. This may be done in duplicate.
 - Antibiotics may be included to prevent bacterial contamination. These may be added to either the sterile saline or PBS used to prepare the homogenates (e.g., chloramphenicol at 0.05 mg/mL and gentamicin at 0.8 µg/mL) or added to the plates onto which the homogenates are plated (e.g., chloramphenicol at 0.05 mg/mL).
- Incubate the plates at 37°C for at least 24 hours and count the number of colonies for each dilution. Calculate the number of colony-forming units (CFU)/gram of tissue.
 - A longer period of incubation may be used (48 - 72 hours) to allow for the growth of cells damaged but not killed by antifungals

Survival. After the discontinuation of antifungal therapy, monitor the mice at least twice daily or as regularly as the clinical condition dictates until the desired study endpoint is reached (e.g., day 21 post-inoculation).

- Any mouse that appears moribund using the criteria specified above should be humanely euthanized. Record the death as occurring the next day.

Examples of Doses and Dosing Calculations for Caspofungin and Fluconazole

Caspofungin (Cancidas, Merck)

Reconstitute vial of caspofungin acetate powder for injection

- Aseptically add 10.8 mL of 0.9% sodium chloride or sterile water for injection to the 50 mg caspofungin vial
- Gently mix vial until a clear solution is obtained (do not vortex)
- Reconstituted 50 mg vial = 5 mg/mL

Multiply average weight of mice by the dose to determine the amount of drug to administer to each animal (e.g. 1 mg/kg x 0.025 kg = 0.025 mg)

Divide the amount of drug to be administered to each mouse by the volume that will be administered (e.g., 0.025 mg/0.2 mL = 0.125 mg/mL)

Calculate the total volume needed to dose all of the mice (e.g., 4 mL for 20 mice; plus 1 mL overage = 5 mL)

To calculate the volume to remove from the reconstituted vial and the volume needed for the dilution use the formula $C_1V_1 = C_2V_2$

- C_1 = concentration of reconstituted vial
- V_1 = volume to remove from reconstituted vial
- C_2 = concentration of solution to be administered to mice
- V_2 = total volume needed to dose all mice

For example:

$$(5 \text{ mg/mL})(V_1) = (0.125 \text{ mg/mL})(5 \text{ mL})$$
$$V_1 = [(0.125 \text{ mg/mL})(5 \text{ mL})]/5 \text{ mg/mL} = 0.125 \text{ mL}$$

Remove 0.125 mL from reconstituted vial and add to 4.875 mL of 0.9% sodium chloride or sterile water for injection (total volume = 0.125 mL + 4.875 mL = 5 mL)

Gently mix and administer by intraperitoneal injection

Note: We refrigerate the reconstituted vial for up to 1 week and use the same vial for an entire week of dosing removing daily the needed volume for the day's dosing.

Fluconazole (Diflucan, Pfizer)

- Use fluconazole for injection (100 mg/50 mL vial = 2 mg/mL concentration)
- Various manufacturers make this product (e.g. Bedford Laboratories; NDC 55390-194-01)
- Store either refrigerated or at room temperature (do not freeze)

Multiply average weight of mice by the dose to determine the amount of drug to administer to each animal (e.g. 10 mg/kg x 0.025 kg = 0.25 mg)

Divide the amount of drug to be administered to each mouse by the volume that will be administered (e.g., 0.25 mg/0.2 mL = 1.25 mg/mL)

Calculate the total volume needed to dose all of the mice (e.g., 20 mL for 20 mice; plus 10 mL overage = 30 mL)

- For fluconazole, we prepare enough for the entire dosing period (e.g., 5 to 7 days of once daily dosing)

To calculate the volume to remove from the reconstituted vial and the volume needed for the dilution use the formula $C_1V_1 = C_2V_2$

- C_1 = concentration of reconstituted vial
- V_1 = volume to remove from reconstituted vial
- C_2 = concentration of solution to be administered to mice
- V_2 = total volume needed to dose all mice

For example:

$$(2 \text{ mg/mL})(V_1) = (1.25 \text{ mg/mL})(30 \text{ mL})$$
$$V_1 = [(1.25 \text{ mg/mL})(30 \text{ mL})]/2 \text{ mg/mL} = 18.75 \text{ mL}$$

Remove 18.75 mL from reconstituted vial and add to 31.25 mL of 0.9% sodium chloride or sterile water for injection (total volume = 31.25 mL + 18.75 mL = 50 mL)

Gently mix and administer by oral gavage

We prepare enough fluconazole to dose all of the mice for the entire treatment period and store the preparation in the refrigerator.

Note: 10 mg/kg is the largest dose of fluconazole that can be given by oral gavage using a volume of 0.2 mL. This is due to the limited concentration of the IV formulation of fluconazole (2 mg/mL). If higher doses need to be administered (e.g., 20 mg/kg), then the volume of the oral gavage must be increased (e.g., 0.3 - 0.4 mL).

- Alternatively, empty the contents of a 200 mg fluconazole capsule into 10 mL of 0.03% agar (reconstituted in water and autoclaved) to make a suspension of 20 mg/mL. This concentration is sufficient to treat mice at up to 200 mg/kg based on dosing at 10 mL/kg.

References:

1. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard - Third Edition. Wayne, PA: Clinical and Laboratory Standards Institute, **2008** CLSI document M27-A3).
2. Jones T, Federspiel NA, Chibana H, et al. The diploid genome sequence of *Candida albicans*. Proceedings of the National Academy of Sciences of the United States of America **2004**; 101:7329-34.
3. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. Caspofungin dose escalation for invasive candidiasis due to resistant *Candida albicans*. Antimicrob Agents Chemother **2011**; 55:3254-60.
4. Najvar LK, Bocanegra R, Wiederhold NP, et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect **2008**; 14:595-600.
5. Hope WW, Warn PA, Sharp A, et al. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J Infect Dis **2005**; 192:673-80.
6. Howard SJ, Livermore J, Sharp A, et al. Pharmacodynamics of echinocandins against *Candida glabrata*: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents chemother **2011**; 55:4880-7.
7. Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-*Candida* rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis **2006**; 194:256-60.
8. Spellberg BJ, Ibrahim AS, Avenissian V, et al. The anti-*Candida albicans* vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun **2005**; 73:6191-3.
9. Graybill JR, Najvar LK, Holmberg JD, Luther MF. Fluconazole, D0870, and flucytosine treatment of disseminated *Candida tropicalis* infections in mice. Antimicrob Agents Chemother **1995**; 39:924-9.